News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory


10/11/2012 12:12:11 PM

TORRANCE, Calif., Oct. 10, 2012 /PRNewswire/ -- Emmaus Life Sciences, Inc., a specialty pharmaceutical and regenerative medicine company, today issued the following statement in response to an announcement issued October 9, 2012, by AFH Holding & Advisory, LLC.

Emmaus Life Sciences has a pending lawsuit in California against AFH Holding & Advisory, which was filed in July 2012. The Company believes the claims filed by AFH Holding & Advisory in Delaware appear to be nothing more than a reaction to the California lawsuit. The company believes AFH's claims are completely without merit and it will defend them vigorously.

About Emmaus Life Sciences
Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.

For more information, please visit www.emmauslifesciences.com.

Contacts:

Media:
Lori Teranishi for Emmaus Life Sciences, Inc.
415-981-1964
lteranishi@iqprinc.com

Investors:
Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
msheldon@pondel.com

SOURCE Emmaus Life Sciences, Inc.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES